

68714\_Auto\_Edited.docx

**Name of Journal:** World Journal of Transplantation

**Manuscript NO:** 68714

**Manuscript Type:** CASE REPORT

**Potential importance of early treatment of SARS-CoV-2 infection in intestinal transplant patient: a case report**

Clarysse M. et al. SARS-CoV-2 infection in intestinal transplant

Mathias Clarysse, Laurens J Ceulemans, Lucas Wauters, Nicholas Gilbo, Viktor Capiau, Gert De Hertogh, Chris Verslype, Wim Laleman, Diethard Monbaliu, Jacques Pirenne, Tim Vanuytsel

## **Abstract**

### **BACKGROUND**

Predispositions for severe coronavirus disease 2019 (COVID-19) are age, immunosuppression, and co-morbidity. High levels of maintenance immunosuppression render intestinal transplant (ITx) patients vulnerable for severe COVID-19. COVID-19 also provokes several gastroenterological pathologies which were not discussed in ITx, so far.

### **CASE SUMMARY**

During the second European COVID-19 wave in November 2020, an ITx recipient was admitted to the hospital because of electrolyte disturbances due to dehydration. Immunosuppression consisted of Tacrolimus, Azathioprine, and low-dose corticosteroids. During hospitalization, she tested positive on screening COVID-19 nasopharyngeal PCR swab, while her initial test was negative. She was initially asymptomatic and had normal inflammatory markers. Tacrolimus levels were slightly raised, as Azathioprine was temporarily halted. Due to elevated D-dimers at that time, prophylactic low-molecular weight heparin was started. Seven days after the positive test, dyspnea, anosmia and CRP increase (25mg/L) were noted. Remdesivir was administered during five days in total. High stomal output was noted in two consecutive days and several days thereafter. To exclude infection or rejection, an ileoscopy and biopsy were performed and excluded these. Four weeks later, she was discharged from the hospital and remains in good health since then.

### **CONCLUSION**

Early eradication of SARS-CoV-2 in ITx recipients may be warranted to prevent acute rejection provocation by it.

**Key words:** Case Report; COVID-19; Intestinal Transplantation; Outcome; SARS-CoV-2; Treatment

**Core tip:**

Acute rejection is often seen in intestinal transplant (ITx) recipients due to the high immunogenicity of the intestinal graft. However, it might also be provoked by latent presence of viruses, due to the high immunosuppression needs. Recently, chronic latency of SARS-CoV-2 in the intestine has been shown. Hence, early recognition, eradication, and follow-up on intestinal biopsies in ITx recipients might be warranted to prevent the potential acute rejection provocation of the intestinal graft by SARS-CoV-2.

**Abbreviations****5****ACE2:** Angiotensin-converting enzyme 2**CMV:** Cytomegalovirus**COVID-19:** Coronavirus Disease 2019**Ct:** Cycle threshold**EBV:** Epstein-Barr virus**ITx:** Intestinal Transplantation**LMWH:** Low-Molecular Weight Heparin**1****SARS-CoV-2:** Severe Acute Respiratory Syndrome CoronaVirus 2

## INTRODUCTION

Coronavirus disease 2019 (COVID-19), provoked by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), poses a major challenge in intestinal transplantation (ITx), due to the high immunogenicity of the graft, requiring high levels of immunosuppression. In the early phase of the pandemic, patients were treated with hydroxychloroquine<sup>[1]</sup>. The treatment of SARS-CoV-2 in transplant patients altered over time in favor of dexamethasone, antivirals or only supportive therapy<sup>[2-4]</sup>. Next to this, it is known that SARS-CoV-2 provokes gastroenterological manifestations, due to its invasion of the enterocytes<sup>[5]</sup>. It has recently been shown that SARS-CoV-2 remained latent present in the upper gastrointestinal tract, as well as in the small intestine, until at least 3 months post-COVID-19 positivity<sup>[6]</sup>. Several other latent gastrointestinal tract viruses are known to be able to provoke acute rejection of the intestinal graft, due to the high immunosuppression needs in these ITx recipients<sup>[7,8]</sup>. To our knowledge, the influence of SARS-CoV-2-related gastroenterological manifestations in ITx patients or the provoked risk for rejection have not been elucidated so far.

## CASE PRESENTATION

### *Chief complaints*

We recently encountered a SARS-CoV-2 infection in a 41-year-old female ITx-recipient, acquired during hospitalization for dehydration and electrolyte disturbances, during the second European COVID-19 wave in November 2020.

### *History of present illness*

She underwent an isolated intestinal re-transplantation, combined with a kidney, in August 2019 for chronic allograft enteropathy. After her re-ITx, she underwent a conversion of her terminal ileostomy to a low ileorectal anastomosis with protective loopileostomy on 29 September 2020.

### *History of past illness*

Her first isolated ITx was in December 2004 for chronic intestinal pseudo-obstruction with recurrent catheter sepsis. In between the two ITx procedures, she was in good health and never encountered an acute rejection, until she developed chronic allograft enteropathy for which she was back on parenteral nutrition since February 2019.

### *Personal and family history*

Negative.

### *Physical examination*

On admission, on 28 October 2020, she was on tacrolimus (3.5mg bidaily, target trough level: 7-8µg/L), azathioprine (50mg/day), and methylprednisolone (4mg/day). She had no fever, respiratory issues, nor recent contact with a potential COVID-19 positive patient.

### *Laboratory examinations*

She tested negative on SARS-CoV-2 on a nasopharyngeal PCR-test (figure 1). Her lab values revealed an acute deterioration of kidney function and electrolyte disturbances. Six days after admission, on 3 November 2020, she tested positive for SARS-CoV-2 on a screening PCR-test.

### *Imaging examinations*

There were no clinical nor biochemical signs of infection, or chest X-ray alterations.

## FINAL DIAGNOSIS

The final diagnosis of this presented case is mild coronavirus disease 2019 (COVID-19).

## TREATMENT

Azathioprine was temporarily halted, and tacrolimus levels slightly raised towards target trough levels of 8-9µg/L. Prophylactic low-molecular weight heparin (LMWH) was started as D-dimers measured 4110ng/mL (normal ≤500ng/mL). She was

transferred to the COVID-19 low-care ward of our hospital. Five days later, on 8 November 2020, her stomal output increased with 227% up to 2830mL/24hours. As rejection was suspected, ileoscopy via the stoma was performed on 9 November 2020, and ileal biopsies were taken (figure 2). These excluded inflammation or rejection. That same day, anosmia and mild dyspnea with normal oxygen saturation developed. Body temperature increased until 37.8°C and C-reactive protein level was 25mg/L (normal <5mg/L). Remdesivir was intravenously administered for 5 days with 200mg as loading dose and 100mg daily thereafter. After the remdesivir treatment was finished, azathioprine was restarted, and tacrolimus trough levels lowered to standard levels.

#### OUTCOME AND FOLLOW-UP

Weekly SARS-CoV-2 PCR remained positive, until a cycle threshold (Ct)-value of 39.22 was found, 4 weeks after her first positive test, on 30 November 2020, and she was removed from the COVID-19 ward as the internal hospital protocol states when the Ct-value is >29. Stomal output kept on fluctuating for 1 month, with several days of high output (>1200mL/24hours). With adequate fluid replacement, renal function remained stable, and the patient could be discharged on 2 December 2020, remaining in good health since then. SARS-CoV-2 PCR remained negative since then, and 3 months after discharge from the hospital SARS-CoV-2 IgG Nucleocapsid antigen was negative. The patient gave informed consent and ethical approval from the institutional review board was obtained (S64844).

#### DISCUSSION

We present the first report, to our knowledge, of mild COVID-19 in an ITx-patient treated with remdesivir, prophylactic LMWH and temporary interruption of azathioprine. As according to the currently available evidence in transplant recipients, azathioprine was halted, and tacrolimus slightly raised in return<sup>[9,10]</sup>. However, it has recently been shown that solid organ transplant recipients can also be successfully treated without adjustment of immunosuppressive therapy and without any antiviral treatment<sup>[4]</sup>. Our patient was preemptively treated with

remdesivir as antiviral treatment. Up till now, there is not much yet known about remdesivir treatment in solid organ transplant recipients<sup>[11]</sup>. Recent reports have shown its tolerability and safety in kidney transplant recipients, without effects on kidney or liver function<sup>[12,13]</sup>. However, it is strongly advised to regularly monitor liver biochemistry in patients treated with remdesivir, as hepatotoxic side effects have been described<sup>[11,14]</sup>.

Although gastroenterological manifestations, including diarrhea, nausea, vomiting, and loss of appetite are commonly seen in COVID-19 patients, symptomatology was mild in our case and limited to high stomal output<sup>[5,15,16]</sup>. These clinical symptoms might also be suggestive for an acute rejection in ITx recipients, which should be treated with an increase of immunosuppression or pulse corticosteroids, which is opposite in the case of an gastroenterological infectious process<sup>[8]</sup>. This symptomatic overlap renders the cause of the gastroenterological manifestations more difficult and hence influences the treatment strategy. If not treated promptly, acute rejection might eventually lead to intestinal graft loss<sup>[17]</sup>. Only endoscopic evaluation with histopathologic confirmation of acute rejection on biopsy can make a clear differentiation. A recent study showed that D-dimers >1850ng/mL, which was the case in our patient (up to 4110ng/mL), is the best discriminator to find major intestinal mucosal abnormalities at endoscopy in COVID-19 positive patients<sup>[18]</sup>.

It is known that viral entrance of SARS-CoV-2, by the angiotensin-converting enzyme 2 (ACE2) receptor, which is abundantly present in the enterocytes of the gastrointestinal tract, plays a major role<sup>[5,6,18]</sup>. This viral entrance provokes an acute inflammatory response, which coincides with ischemic damage due to the procoagulant state and endothelialitis, which has also been observed in ITx rejection<sup>[17,18]</sup>. Several other viruses have already shown to mimic intestinal graft rejection by crypt apoptosis, such as Cytomegalovirus (CMV), Epstein-Barr virus (EBV), adeno- and norovirus<sup>[7,8]</sup>. Close monitoring, during the postinfectious period of these viruses, is also important as the infection might provoke acute rejection of the intestinal graft<sup>[8]</sup>. For SARS-CoV-2, such a correlation has not been shown so far. However, as it has been shown by Gaebler *et al.*, SARS-CoV-2 can remain latent present in even asymptomatic patients at least 3 months post-COVID-19<sup>[6]</sup>. As SARS-



CoV-2 is able to enter the enterocytes by the ACE2-receptor and provoke an acute inflammatory response, it is hypothetically possible that SARS-CoV-2 might mimic or provoke acute rejection of the intestinal graft in ITx recipients as well. As such, follow-up of SARS-CoV-2 antigen on routine or screening, rejection/infection suspicion, biopsies of the intestinal allograft might be performed in previous, current or suspected COVID-19 positive ITx recipients, as is currently the case for CMV<sup>[7]</sup>. Early treatment and eradication of intestinal SARS-CoV-2 may be warranted to prevent the potential acute rejection mimicry or provocation.

SARS-CoV-2 nucleocapsid (N) antibodies assay, on the Abbott Architect system, was negative in our patient, despite SARS-CoV-2 positive PCR 3 months earlier. However, it has been shown that SARS-CoV-2 IgG anti-N are positive in only 62% of SARS-CoV-2 PCR positive transplant recipients 1-2 months post-infection. Whilst these are decreasing towards only 55% at 3-4 months and even 38% at 5-7 months post-infection. This decline in anti-N is mainly seen in mild disease form<sup>[19]</sup>. SARS-CoV-2 spike (S) antibodies, on the contrary, are more durable with IgG anti-S present in 92% at 1-2 months, 84% at 3-4 months and even 76% at 6-7 months post-infection in transplant recipients<sup>[4]</sup>. Next to this, the analysis was run on the Abbott Architect system, of which it has been shown that it is less sensitive in transplant recipients, in comparison to non-transplant recipients, and in comparison to other assets, due to a different targeting antigen<sup>[20]</sup>. It is proposed that the spike antigen is more immunogenic than the nucleocapsid antigen in immunosuppressed patients<sup>[20]</sup>. On top of that, there is evidence that spike antibodies may provide functional immunity information, as there is a correlation between spike antibodies and neutralizing antibodies<sup>[21,22]</sup>. As such, analyzing the anti-S might be clinically more relevant than the anti-N in immunosuppressed patients<sup>[20]</sup>.

## CONCLUSION

Early treatment of SARS-CoV-2 should be considered in ITx recipients, in order to eradicate the virus to prevent acute rejection mimicry or provocation and potential graft loss. SARS-CoV-2 antigen determination on ileal biopsies of ITx recipients

might be routinely performed to screen for the hypothesis of SARS-CoV-2 acute rejection mimicry or provocation.

## ORIGINALITY REPORT

4%

SIMILARITY INDEX

### PRIMARY SOURCES

- |  |  |               |
|--|--|---------------|
| <div style="background-color: red; color: white; padding: 5px; display: inline-block; width: 30px; height: 30px; text-align: center; line-height: 30px;">1</div>     | <a href="http://www.cell-stress.com" style="color: red;">www.cell-stress.com</a><br><small>Internet</small>  | 26 words — 1% |
| <hr/>  |  |               |
| <div style="background-color: magenta; color: white; padding: 5px; display: inline-block; width: 30px; height: 30px; text-align: center; line-height: 30px;">2</div> | <a href="http://www.ncbi.nlm.nih.gov" style="color: magenta;">www.ncbi.nlm.nih.gov</a><br><small>Internet</small>  | 15 words — 1% |
| <hr/>  |  |               |
| <div style="background-color: purple; color: white; padding: 5px; display: inline-block; width: 30px; height: 30px; text-align: center; line-height: 30px;">3</div>  | <a href="#" style="color: purple;">Clarysse M, Wauters L, Gilbo N, Monbaliu D, Pirenne J, Vanuytsel T. "P-81: COVID-19 Outcome in an Isolated Intestinal Transplant Recipient", Transplantation, 2021</a><br><small>Crossref</small>       | 14 words — 1% |
| <hr/>  |  |               |
| <div style="background-color: teal; color: white; padding: 5px; display: inline-block; width: 30px; height: 30px; text-align: center; line-height: 30px;">4</div>    | <a href="http://v3r.esp.org" style="color: teal;">v3r.esp.org</a><br><small>Internet</small>   | 13 words — 1% |
| <hr/>  |  |               |
| <div style="background-color: green; color: white; padding: 5px; display: inline-block; width: 30px; height: 30px; text-align: center; line-height: 30px;">5</div>   | <a href="#" style="color: green;">Andri Frediansyah, Ruchi Tiwari, Khan Sharun, Kuldeep Dhama, Harapan Harapan. "Antivirals for COVID-19: A critical review", Clinical Epidemiology and Global Health, 2020</a><br><small>Crossref</small> | 12 words — 1% |

EXCLUDE QUOTES ON

EXCLUDE MATCHES

< 12 WORDS

EXCLUDE BIBLIOGRAPHY ON